Faslodex Injection
PDF Leaflet Revision Date: 7 June 2019
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women.
Dosage (summary)
500 mg intramuscularly as two 5 ml injections, one in each buttock, at 1-month intervals with an additional 500 mg dose 2 weeks after the initial dose.
Special Populations
- Hepatic impairment
- Renal insufficiency
Pregnancy & Breastfeeding
Avoid use in pregnancy and breastfeeding; potential reproductive toxicity.
Key Drug Interactions
- CYP3A4 inhibitors
- CYP3A4 inducers
Contraindications
- Hypersensitivity to ingredients
- Severe hepatic impairment
- Pregnancy
- Breastfeeding
Common side effects
- Injection site reactions
- Asthenia
- Nausea
- Hypersensitivity reactions
- Joint pain
- Hot flushes
Counselling Points
- Administer slowly
- Monitor for hypersensitivity reactions
- Avoid driving if experiencing asthenia
Serious warnings
- Caution in hepatic impairment
- Caution in renal impairment
- Injection site related events
Important Disclaimer
The Faslodex Injection professional information leaflet below is the property of Astrazeneca Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
